Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis.

Related Articles

Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis.

Allergy Asthma Proc. 2012 May-Jun;33(3):249-57

Authors: Meltzer EO, Jacobs RL, LaForce CF, Kelley CL, Dunbar SA, Tantry SK

Abstract
Intranasal corticosteroids are recommended as first-line therapy for the treatment of the symptoms of persistent allergic rhinitis (AR). Since the phase-out of chlorofluorocarbon nasal aerosols, intranasal corticosteroids have been available only as aqueous nasal sprays. This study was designed to assess the efficacy, safety, and quality-of-life benefits of beclomethasone dipropionate (BDP) hydrofluoroalkane nasal aerosol in subjects with perennial AR (PAR). After a 7- to 21-day placebo run-in period, eligible subjects aged â�¥12 years with PAR were randomized to 6 weeks of once-daily treatment with BDP nasal aerosol at 320 �¼g or placebo. Reflective and instantaneous total nasal symptom scores (rTNSS and iTNSS, respectively), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, and physician-assessed total nasal symptom score were evaluated. The primary end point was change from baseline in average morning (A.M.) and evening (P.M.) subject-reported rTNSS over the 6-week treatment period. Safety and tolerability were also assessed. Treatment with BDP nasal aerosol showed significantly greater improvement in average A.M. and P.M. rTNSS compared with placebo (mean treatment difference, -0.84; 95% confidence interval, -1.2, -0.5; p < 0.001). Greater improvements in rTNSS were reported as early as day 1 and were maintained throughout the 6-week treatment period with the exception of day 2. Greater improvements were seen for all four individual nasal symptoms (nasal congestion, nasal itching, rhinorrhea, and sneezing) with BDP nasal aerosol compared with placebo. Similarly, significant improvements were seen in average A.M. and P.M. iTNSS (p < 0.001) and RQLQ score (p = 0.001) with BDP nasal aerosol compared with placebo. In addition, BDP nasal aerosol treatment was well tolerated, and its safety profile was comparable to that of placebo. This clinical study indicated that treatment with BDP nasal aerosol provides statistically significant and clinically meaningful nasal symptom relief accompanied by improved quality of life in subjects with PAR. Additionally, treatment with BDP nasal aerosol was well tolerated with a safety profile comparable to that of placebo. This study was part of the clinical trial NCT01134705 registered in www.ClinicalTrials.gov.

PMID: 22737708 [PubMed – in process]

View full post on pubmed: asthma

Actelion to end setipiprant clinical development in asthma, allergic rhinitis – RTT News

Actelion to end setipiprant clinical development in asthma, allergic rhinitis
RTT News
PK: News ) on Monday said two recently concluded studies with the first orally-active CRTH2 antagonist, setipiprant, in asthma and seasonal allergic rhinitis did not confirm efficacy findings made in earlier studies. Accordingly, the company is
Actelion provides update on CRTH2 programReuters

all 11 news articles »

View full post on asthma – Google News

[The approaches to diagnostics and therapy of allergic rhinitis].

[The approaches to diagnostics and therapy of allergic rhinitis].

Vestn Otorinolaringol. 2011;(5):62-5

Authors:

Abstract
Allergic rhinitis is a common disease of great socio-economic significance. The treatment of this condition is carried out on an individual basis depending on the clinical course of the disease; it includes prevention of contacts with the allergen, medicamental and immunotherapy. The principal pharmaceuticals used to treat the patients include oral and intranasal H1 anti-histaminic preparations, intranasal corticosteroids, intranasal cromones, anti-leukotrien agents, and specific subcutaneous immunotherapy. Glencet (levocetirizine) is one of the modern antihistaminic preparations of the second generation having an advantage over other drugs for the treatment of allergic rhinitis in that it may be prescribed to the patients presenting with concomitant bronchial asthma and cardiac diseases.

PMID: 22334929 [PubMed – in process]

View full post on pubmed: asthma

Allergic Rhinitis Affects 40% of Children Worldwide and Prevalence Is Increasing – PR Web (press release)

Allergic Rhinitis Affects 40% of Children Worldwide and Prevalence Is Increasing
PR Web (press release)
Allergic rhinitis is a complex disease involving several associated disorders and is a risk factor for asthma, requiring treatment of multiple conditions. It affects 10% to 30% of adults and 40% of children worldwide, estimated at 400 million people by

and more »

View full post on asthma – Google News

Research and Markets: the Asthma, COPD & Allergic Rhinitis Market Outlook to … – Business Wire (press release)

Research and Markets: the Asthma, COPD & Allergic Rhinitis Market Outlook to
Business Wire (press release)
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical

and more »

View full post on asthma – Google News

Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016 – Centre Daily Times

Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
Centre Daily Times
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical

and more »

View full post on asthma – Google News

Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016 – SYS-CON Media (press release)

Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
SYS-CON Media (press release)
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical

and more »

View full post on asthma – Google News